Expenditure was distributed differently for each cardiovascular condition. To illustrate, in 2018–19:
- hospital services represented 83% of CHD expenditure, 61% of AF expenditure, and 90% of stroke expenditure
- non-hospital medical services represented 9.4% of CHD expenditure, 11% of AF expenditure, and 7.1% of stroke expenditure
- Pharmaceutical Benefits Scheme costs represented 6.6% of CHD expenditure, 28% of AF expenditure, and 3.0% of stroke expenditure.
Who is it spent on?
Expenditure on CVD in 2018–19 was low among young people, but increased sharply from age 45–54 years, to be highest among males aged 65–74 and females aged 75–84 (Figure 3).
From age 45–54 years, expenditure on CVD was higher among males than females, except at age 85 and over, reflecting the higher prevalence of CVD among males. At ages 55–64, 60–64 and 65–74 years, expenditure for males was 1.7 times as high as for females.
Most of this difference was related to expenditure on hospital services, where a total of $4.9 billion was spent on males, compared with $3.2 billion on females.
Expenditure on non-hospital medical services (primary care) was higher among females ($902 million, compared to $887 million among males), despite the higher prevalence of CVD among males.
Expenditure in the area of prescription pharmaceuticals was higher among males ($951 million) compared to females ($848 million).
Figure 3: Health care expenditure on cardiovascular disease, by age and sex, 2018–19